

# Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis

Yolanda Bravo Vergel, Stephen Palmer, Christian Asseburg, Elisabeth Fenwick, Mark de Belder, Keith Abrams, Mark Sculpher



This paper is freely available online under the BMJ Journals unlocked scheme, see <http://heart.bmj.com/info/unlocked.dtl>

Heart 2007;93:1238–1243. doi: 10.1136/hrt.2006.111401

**Objective:** To assess the cost effectiveness of primary angioplasty, compared with medical management with thrombolytic drugs, to achieve reperfusion after acute myocardial infarction (AMI) from the perspective of the UK NHS.

**Design:** Bayesian evidence synthesis and decision analytic model.

**Methods:** A systematic review was conducted and Bayesian statistical methods used to synthesise evidence from 22 randomised control trials. Resource utilisation was based on UK registry data, published literature and national databases, with unit costs taken from routine NHS sources and published literature.

**Main outcome measure:** Costs from a health service perspective and outcomes measured as quality-adjusted life years (QALYs).

**Results:** For the base case, the incremental cost-effectiveness ratio of primary angioplasty was £9241 for each additional QALY, with a probability of being cost effective of 0.90 for a cost-effectiveness threshold of £20 000. Results were sensitive to variations in the additional time required to initiate treatment with primary angioplasty.

**Conclusions:** Primary angioplasty is cost effective for the treatment of AMI on the basis of threshold cost-effectiveness values used in the NHS and subject to a delay of up to about 80 minutes. These findings are mainly explained by the superior mortality benefit and the prevention of non-fatal outcomes associated with primary angioplasty for delays of up to this length.

See end of article for authors' affiliations

Correspondence to:  
Dr M Sculpher, Centre for Health Economics, University of York, Heslington, YO10 5DD York, UK;  
mjs23@york.ac.uk

Accepted 23 May 2007

Effective and cost-effective management of coronary heart disease in the UK is an NHS priority. In particular, the timely and efficient management of acute myocardial infarction (AMI) comprises the cornerstone of the Coronary Heart Disease National Service Framework.<sup>1</sup> Although the management of AMI has improved in the UK, with an associated 16% reduction in mortality between 1999 and 2001<sup>2</sup> reducing the gap in death rates between this country and others in Europe,<sup>3,4</sup> many of these deaths are still considered to be potentially preventable.

Thrombolysis remains the predominant reperfusion strategy for ST-segment elevation myocardial infarction in the UK, but its use has limitations. In particular, normal coronary flow is restored in only 25–50% of patients, depending on the choice of thrombolytic drug.<sup>5</sup> The increased use of primary angioplasty has been suggested as one approach to improve further the management of patients with AMI.<sup>6</sup> However, the question of whether primary angioplasty should become the first-line treatment in the UK is still the subject of considerable debate.<sup>7,8</sup>

The Department of Health and the British Cardiac Society have recently set up the National Infarct Angioplasty Project (NIAP), a study to assess the feasibility of implementing a national primary angioplasty service in 10 NHS pilot centres across England.<sup>3,9</sup> Apart from the logistic and economic implications derived from any structural change in healthcare provision, one possible reason for the limited use of primary angioplasty in the UK NHS is the lack of evidence about its cost effectiveness: no studies have been published relating to UK practice and expressing outcomes as quality-adjusted life years (QALYs), which facilitate comparison with other uses of health service resources. Our aim was to develop a UK-specific cost-effectiveness model of primary angioplasty compared with thrombolysis on the basis of existing evidence.

## METHODS

### Overview


A probabilistic decision analytic model was constructed. A systematic review was conducted to update the most comprehensive meta-analysis in this area,<sup>10</sup> and Bayesian statistical methods were used to synthesise the effectiveness evidence from 22 randomised control trials.<sup>11</sup> The model was developed as a comprehensive decision analysis,<sup>12,13</sup> where the individual components of the decision modelling were dealt with simultaneously and evaluated using a Markov Chain Monte Carlo simulation implemented in the specialist software WinBUGS.<sup>14</sup>

QALYs were used as the measure of health outcome. The structure of the decision analytic model and its underlying assumptions were developed in discussion with a group of clinical advisors, all experienced consultant cardiologists from the UK. The model considered the costs from the perspective of the NHS, using 2003–4 prices, with costs and benefits discounted at 3.5% a year.<sup>15</sup> Details of the updated systematic review and evidence synthesis are presented in a companion paper to this.<sup>11</sup> Full technical details of all methods can be found in a technical report (available at <http://heart.bmj.com/supplemental>).

### Model structure

The decision model comprised two main elements: a decision tree that captured the short-term events and costs associated

**Abbreviations:** AMI, acute myocardial infarction; CrI, credible interval; GPAs, glycoprotein IIb/IIIa antagonists; ICER, incremental cost-effectiveness ratio; MI, myocardial infarction; NHAR, Nottingham Heart Attack Registry; NIAP, National Infarct Angioplasty Project; OR, odds ratio; QALYs, quality-adjusted life years



**Figure 1** Overview of the model structure. IHD, ischaemic heart disease; MI, myocardial infarction; RCTs, randomised controlled trials.

with the management of AMI using either thrombolysis or primary angioplasty up to 6 months after an initial AMI episode; and a long-term Markov model,<sup>16</sup> which extrapolated the analysis to a lifetime time horizon using an annual cycle. Figure 1 provides a schematic diagram of the model structure. More information about the model and a detailed diagrammatic representation are provided in the technical report.<sup>17</sup>

Event rates with thrombolysis (referred to as “baseline” event rates) were multiplied by the pooled odds ratios (ORs) estimated from the evidence synthesis to quantify the absolute effect of primary angioplasty. The possibility of needing a further revascularisation was also modelled. The short-term model was used to determine, for each treatment, the costs incurred during the initial 6 months after treatment. In addition, it established the proportions of patients that entered the different health states of the long-term extrapolation model: death, alive without further events (ischaemic heart disease state (IHD)), repeated non-fatal myocardial infarction (MI) and non-fatal stroke. The long-term extrapolation provided an estimate of lifetime costs and QALYs conditional on surviving the first 6 months.

**Model inputs**  
**Clinical effectiveness**

Table 1 presents the clinical effectiveness inputs used to inform the cost-effectiveness model. Bayesian evidence synthesis was used to inform the clinical effectiveness measures for the short-term model, based on an average of all streptokinase and fibrin-specific trials.<sup>11</sup> Outcomes were estimated as a function of the additional time delay associated with primary angioplasty compared with thrombolysis defined as the mean difference between time-to-balloon in primary angioplasty and time-to-needle in thrombolysis (mean (SE) 54.3 (2.2) minutes).

The base-case analysis establishes the cost effectiveness of primary angioplasty on the assumption that the average patient is treated as in the randomised trials included in the meta-analysis, and in centres that have the necessary infrastructure. As a result, the angioplasty-related time delay applied in the base-case analysis is based on the average figure reported across the trials (54.3 minutes). A series of sensitivity analyses were also undertaken to explore the impact of variation in the estimate of time delay on the cost-effectiveness results. Separate analyses were undertaken for delays of 30, 60 and 90 minutes. Table 1 also shows the pooled odds ratios applied at these different time delays.

Table 2 summarises the main input variables and sources applied in the cost-effectiveness model. The various components are described below.

**Resource use and costs during the short-term period (6 months)**

The resources considered include those associated with the initial interventions (eg, drug acquisition costs, procedure costs and associated hospital length of stay) and subsequent events occurring over the following 6 months, such as further revascularisations and major clinical events (either repeat MI or stroke). For the base-case analysis, we used national statistics on the average length of hospital stay for patients with AMI based on Hospital Episode Statistics.<sup>18</sup> Hence, in the absence of reliable data with which to quantify the potential impact of primary angioplasty on the length of the initial hospitalisation, we applied a conservative approach by assuming that primary angioplasty has no impact on the duration of hospitalisation (ie, we assumed a mean length of stay of 10 days for each strategy). A separate sensitivity analysis was also conducted<sup>17</sup> using estimates from a sample of 80 patients from Hammersmith and Charing Cross Hospital, in order to assess the implications of a shorter length of stay with primary angioplasty than with thrombolysis (Morgan K, personal communication, 2005).

We also applied a conservative assumption about resource use and costs for all consumables and adjunctive drugs used with primary angioplasty. The base-case analysis assumed that all patients receiving primary angioplasty would receive an angiogram, adjunctive glycoprotein IIb/IIIa antagonists (GPAs) and stents during the initial procedure, although, in reality, the use of these adjunctive treatments is likely to vary between different hospitals. Reflecting their use in the trials, the unit cost of bare metal stents was used. Drug costs were taken from the British National Formulary,<sup>19</sup> based on licensed dosages. Other unit costs were obtained from NHS reference costs<sup>20</sup> and published literature.<sup>21 22</sup>

**Long-term event rates and costs**

The long-term implications of two short-term (“prognostic”) events were modelled over the long term: non-fatal MIs and non-fatal strokes. In the absence of long-term trial evidence on the prognosis of these patients after primary angioplasty or thrombolysis, UK registry data were used to calculate long-term event rates and associated costs. This “extrapolation modelling” assumed no

**Table 1** Clinical effectiveness measures based on the evidence synthesis results<sup>11 17</sup>

	Base-case value	Low CrI	High CrI
<b>Probability of an event with thrombolysis</b>			
Death	0.07	0.05	0.11
Non-fatal reinfarction	0.06	0.04	0.10
Non-fatal stroke	0.02	0.01	0.06
<b>Odds ratios—primary angioplasty effect</b>			
Average time delay (54 min)			
Death	0.70	0.42	1.18
Non-fatal reinfarction	0.33	0.20	0.67
Non-fatal stroke	0.26	0.08	0.72
30 Minutes' delay			
Death	0.54	0.29	0.92
Non-fatal reinfarction	0.30	0.14	0.59
Non-fatal stroke	0.47	0.05	0.69
60 Minutes' delay			
Death	0.77	0.44	1.29
Non-fatal reinfarction	0.39	0.21	0.72
Non-fatal stroke	0.56	0.09	0.75
90 Minutes' delay			
Death	1.15	0.49	2.36
Non-fatal reinfarction	0.55	0.29	1.27
Non-fatal stroke	0.79	0.08	1.43

Results are posterior mean distributions and 95% credible interval (CrI).

**Table 2** Summary of other variables associated with the base-case model

Variables	Base-case value	Low CrI	High CrI	Distribution	Source
<b>Probabilities of further revascularisations</b>					
Primary angioplasty					
Repeated angioplasty	0.054	–	–	Beta ( $\alpha = 19$ , $\beta = 319$ )	Systematic review <sup>11 17</sup>
CABG	0.054	–	–	Beta ( $\alpha = 18$ , $\beta = 290$ )	Systematic review <sup>11 17</sup>
Thrombolysis					
Angioplasty (rescue and routine)	0.281	–	–	Beta ( $\alpha = 27$ , $\beta = 69$ )	Systematic review <sup>11 17</sup>
CABG	0.071	–	–	Beta ( $\alpha = 18$ , $\beta = 222$ )	Systematic review <sup>11 17</sup>
<b>Transition probabilities*†</b>					
From IHD state to non-fatal event (year 1)	0.059	0.041	0.077	Log normal	NHAR <sup>23</sup>
From IHD to non-fatal event ( $\geq 2$ years)	0.027	0.019	0.036	Log normal	NHAR <sup>23</sup>
From IHD to CV death (year 1)	0.038	0.024	0.055	Log normal	NHAR <sup>23</sup>
From IHD to CV death ( $\geq 2$ years)	0.032	0.023	0.041	Log normal	NHAR <sup>23</sup>
From non-fatal event to CV death (year 1)	0.260	0.180	0.352	Log normal	NHAR <sup>23</sup>
From non-fatal event to CV death ( $\geq 2$ years)	0.048	0.021	0.084	Log normal	NHAR <sup>23</sup>
Recurrent non-fatal event in the MI state	0.087	0.049	0.134	Posterior distribution	NHAR <sup>23</sup>
Recurrent non-fatal event in the stroke state	0.038	0.017	0.182	Posterior distribution	NHAR <sup>23</sup>
Recurrent stroke	0.498	0.095	0.906	Posterior distribution	NHAR <sup>23</sup>
Hospital length of stay after acute MI (days)	10	–	–	Fixed	HES <sup>18</sup>
<b>Unit costs (£) treatment initial acute MI episode‡</b>					
Cardiac ward	173	–	–	Fixed	20
Angiography (procedure)	727	–	–	Fixed	21
Primary angioplasty (procedure)	1614	–	–	Fixed	21
Guidewire	71	–	–	Fixed	21
Bare metal stent	370	–	–	Fixed	22
Guiding catheter	42	–	–	Fixed	21
Balloon	231	–	–	Fixed	21
Abciximab	1042	–	–	Fixed	22
Streptokinase	89.72	–	–	Fixed	22
Alteplase	600	–	–	Fixed	22
<b>Unit costs (£) events after initial episode‡</b>					
Acute MI (episode)	1055	–	–	Fixed	20
Primary angioplasty (procedure)	2984	–	–	Fixed	20
CABG (procedure)	6450	–	–	Fixed	29
<b>Long-term costs associated with health states*§</b>					
IHD state	431	99	1209	Posterior distribution	Technical report <sup>17</sup>
MI state (year 1)	1964	1368	3150	Posterior distribution	Technical report <sup>17</sup>
After MI state ( $\geq 2$ years)	91	375	1188	Posterior distribution	Technical report <sup>17</sup>
Stroke state (year 1)	8786	8244	9395	Posterior distribution	Technical report <sup>17</sup>
After stroke ( $\geq 2$ years)	2318	1826	2933	Posterior distribution	Technical report <sup>17</sup>
<b>Utilities associated with health states</b>					
MI state (year 1)	0.683	–	–	Beta ( $\alpha = 624$ , $\beta = 289$ )	Measured 6 months after hospital discharge <sup>25</sup>
After MI state ( $\geq 2$ years)	0.718	–	–	Beta ( $\alpha = 564$ , $\beta = 222$ )	Measured 12 months after hospital discharge <sup>25</sup>
Non-disabled stroke	0.740	–	–	Beta ( $\alpha = 219$ , $\beta = 78$ )	26
Disabled stroke	0.380	–	–	Beta ( $\alpha = 43$ , $\beta = 70$ )	26
Combined stroke	0.612	–	–	–	26

CABG, coronary artery bypass grafting; CrI, credible interval; CV, cardiovascular; IHD, ischaemic heart disease; MI, myocardial infarction.

\*Mean and 95% CrI reported.

†Hazard rates obtained from survival analysis, converted to probabilities.

‡Price year 2003–4; all costs updated using HCHS<sup>27</sup> price index 2004.

§All annual costs adjusted by average number of days spent in each state based on NHAR dataset.

continued treatment effect difference between thrombolysis and angioplasty beyond 6 months. The Nottingham Heart Attack Registry (NHAR)<sup>23</sup> was used to estimate resource use and transition probabilities for the long-term model. NHAR was selected because extensive follow-up data had been collected (5-years' follow-up) and provided detailed information on both the frequency and timing of recurrent events as well as resource utilisation. Transition probabilities were calculated from the NHAR data using survival analysis techniques. Although non-cardiac mortality was recorded in the NHAR, the probability of non-cardiac mortality was based on UK life tables owing to the small number of these events.<sup>2</sup>

### Quality adjustment

To estimate QALYs, it is necessary to quality adjust the period of time the average patient is alive within the model using an appropriate utility or preference score. In the absence of utility data from the trials and the NHAR, external estimates of utility data were sought in order to differentiate between the health status of patients according to the different states of the model. A literature review was undertaken to obtain estimates of utilities for the different long-term health states. A single utility score for patients with a stroke was applied, which was weighted by the probability that this event was disabling or not.<sup>24</sup>

**Table 3** Cost-effectiveness results

Time delay	Strategy	Mean costs (£)	Mean QALYs	ICER (£)	Probability of being cost effective for threshold of:		
					£10 000	£20 000	£30 000
<b>Base-case analysis</b>							
Average delay (54 min)	Primary angioplasty	12 760	7.12	9 241	0.55	0.90	0.95
	Thrombolysis	10 080	6.83	–	0.45	0.10	0.05
<b>Time delays of:</b>							
30 Minutes	Primary angioplasty	12 820	7.23	6 850	0.82	0.98	0.99
	Thrombolysis	10 080	6.83	–	0.18	0.02	0.01
60 Minutes	Primary angioplasty	12 750	7.09	10 269	0.43	0.83	0.91
	Thrombolysis	10 080	6.83	–	0.57	0.17	0.09
90 Minutes	Primary angioplasty	12 670	6.87	64 750	0.13	0.36	0.45
	Thrombolysis	10 080	6.83	–	0.87	0.64	0.55
<b>Differential length of hospital stay*</b>							
Average delay (54 min)	Primary angioplasty	12 030	7.12	5 448	0.82	0.95	0.97
	Thrombolysis	10 450	6.83	–	0.18	0.05	0.03
30 Minutes	Primary angioplasty	12 085	7.23	4 087	0.95	0.99	0.99
	Thrombolysis	10 450	6.83	–	0.05	0.01	0.01
60 Minutes	Primary angioplasty	12 020	7.09	6 038	0.75	0.91	0.99
	Thrombolysis	10 450	6.83	–	0.25	0.09	0.01
90 Minutes	Primary angioplasty	11 940	6.87	37 250	0.32	0.47	0.52
	Thrombolysis	10 450	6.83	–	0.68	0.53	0.48


ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life years.

\*Using an estimate of 5.8 days (SE 1.6) for primary angioplasty and 12.1 days (SE 2.9) for thrombolysis (Morgan K, personal communication, 2005).

**Analytical methods**

The model was run probabilistically and the uncertainty in the individual measures was fully characterised using the probability distributions summarised in table 2. The results of the model are presented in two ways. First, mean lifetime costs and QALYs for both strategies are reported and their cost effectiveness presented using incremental cost-effectiveness ratios (ICERs).<sup>28</sup> Second, decision uncertainty is presented as the probability that each intervention is considered the more cost effective for a given cost-effectiveness threshold.

The following analyses are undertaken. First, the impact on the cost-effectiveness results of a range of alternative time delays (30, 60 and 90 minutes) is explored. Second, the base-case assumption of equal durations of initial hospital stays with both treatments is relaxed and the impact of differential lengths of initial hospitalisation stay (5.8 days (SE 1.6) for primary angioplasty; 12.1 (SE 2.9) for thrombolysis) (Morgan K, personal communication, 2005) assessed. Third, the implications of higher costs for primary angioplasty because of the need to invest in new infrastructure in hospitals without existing facilities are explored.



**Figure 2** Threshold analysis: impact of varying additional investment costs per patient compared with the base-case analysis for different time delay scenarios. QALY, quality-adjusted life year.

**RESULTS**

**Clinical effectiveness**

The full clinical results from the evidence synthesis have been published.<sup>11</sup> Briefly, the results showed that for the average time delay (54 minutes) the mean event probabilities were lower for primary angioplasty for all outcomes. Mortality within 6 months was 5.5% after angioplasty and 7.7% after thrombolysis (OR = 0.70; 95% credible interval (CrI) 0.42 to 1.18). For non-fatal re-infarction, the OR was 0.33 (95% CrI 0.20 to 0.67); and for non-fatal stroke 0.26 (95% CrI 0.08 to 0.72). For all outcomes, the benefit of angioplasty decreased with longer treatment initiation delay (table 1).

**Cost effectiveness: base-case analysis**

Table 3 presents the base-case results. Primary angioplasty is the most expensive option (mean lifetime costs £12 760 vs £10 080), but it was also associated with a mean lifetime QALY gain of 0.29 (7.12 vs 6.83). The ICER associated with primary angioplasty compared with thrombolysis was £9241 for each additional QALY, hence primary angioplasty will be the optimal treatment provided that the NHS is prepared to pay at least this amount. The probability that primary angioplasty is cost effective is around 0.55 for a cost-effectiveness threshold of £10 000, increasing to almost 1 for a threshold of £30 000 per QALY.

**Cost effectiveness: alternative scenarios**

Reducing the time delay to 30 minutes improves the estimate of cost effectiveness, with a reduction of the ICER to £6850 per QALY. Furthermore, the probability that this strategy is cost effective is 0.82 at a threshold of £10 000, increasing to close to 1 for a threshold of £20 000 and above. These results are explained by a higher mortality benefit at 30 minutes (OR = 0.54; 95% CrI 0.29 to 0.92) and a slightly higher prevention of non-fatal reinfarction than those estimated based on the average time delay.

As expected, results at 60 minutes were similar to those for average time delay, but increasing the time delay up to 90 minutes resulted in a sevenfold increase in the base-case ICER (£64 750 per QALY) and a substantial reduction in the

probability that primary angioplasty was considered cost effective at conventional thresholds considered to represent value for money in the NHS.<sup>15</sup> This is explained by the fact that no additional mortality benefit is apparent with primary angioplasty for 90 minutes' delay in starting treatment.

The alternative setting with lower length of initial hospitalisation with primary angioplasty (5.76 days compared with 12.12 days for the thrombolytic strategy) showed an improvement in the estimate of cost effectiveness, with a reduction of the ICER for all time delays. In this setting, even for a delay up to 90 minutes, primary angioplasty was the optimal strategy for a threshold of £30 000.

The cost-effectiveness results presented here are based on the assumption that centres already have the necessary infrastructure to provide primary angioplasty. Figure 2 presents a threshold analysis showing the impact of additional investment costs in new facilities for primary angioplasty that may be necessary in some centres. This represents an "up front" capital investment allocated per patient for primary angioplasty. This demonstrates that, in cases where the additional investment costs are up to the equivalent of £9000 per patient and when the additional time delay associated with primary angioplasty over thrombolysis is no higher than 60 minutes, the cost effectiveness of primary angioplasty would be in the region of £20 000 to £40 000 per QALY. In those cases where additional investment cost per patient is higher than £9000, thrombolysis is the optimal strategy.

## DISCUSSION

Several studies have looked at the economics of primary angioplasty.<sup>29–31</sup> For decision making in the UK NHS, however, a cost-effectiveness analysis should have some key features.<sup>15</sup> These include the incorporation of all relevant trial evidence on clinical effects, the expression of outcomes as QALYs for comparison across clinical areas and the use of UK costs. Some studies have been based on systematic reviews of clinical effects,<sup>29</sup> two used QALYs<sup>30–31</sup> and one UK costs,<sup>29</sup> but we are not aware of any existing study with all these features.

Despite hitherto limited evidence for its cost effectiveness, widening the use of primary angioplasty in the UK NHS is already being considered. Findings from the NIAP project, due in 2008, will inform policy on the provision of primary angioplasty as a first treatment for patients who have a heart attack.<sup>3–9</sup> Results from the analysis presented here suggest that primary angioplasty is cost effective based on the cost-effectiveness thresholds used by the National Institute for Health and Clinical Excellence (£20 000 to £30 000 per additional QALY<sup>15–32</sup>). This conclusion, however, is sensitive to the additional time delay associated with primary angioplasty. The results from the different scenarios suggest that primary angioplasty may not be cost effective for an additional delay somewhere within the region of 60 to 90 minutes. An additional analysis was undertaken to identify the time at which primary angioplasty no longer seems to be cost effective compared with thrombolysis. At a cost-effectiveness threshold of £20 000 per QALY, primary angioplasty appears cost effective for delays of less than 79 minutes (and 84.5 minutes at £30 000 per QALY). The cost effectiveness of primary angioplasty may also be sensitive to the set-up costs of the service.

The comprehensive decision modelling methods used in the analyses presented here allow both evidence synthesis and decision analytical models to be combined within a single coherent modelling framework, which not only allows all sources of uncertainty to be appropriately propagated throughout the analysis, and consequently included in the overall cost-effectiveness estimates, but also allows appropriate consideration of the correlation induced when the same evidence source

contributes to multiple components of the decision model.<sup>12</sup> The Bayesian approach also enables the inclusion of complex data structures and networks of evidence without the need to make distributional assumptions about model inputs.<sup>12–13–33</sup>

In addition to handling the uncertainty in the evidence, it is also important to reflect variation—for example, in clinical context and practice, resource use and costs between hospitals. Analyses of various scenarios have been used here to assess the implications of additional time delay in providing angioplasty, differential lengths of hospital stay and additional investment cost in new facilities. These show the likely boundaries of the cost effectiveness of primary angioplasty. Each input into the analysis is estimated with uncertainty but, using probabilistic methods, the analysis shows that, for most settings, primary angioplasty has the highest probability of being cost effective even at lower cost-effectiveness thresholds. However, the remaining decision uncertainty may indicate that further primary research into the costs and effects of primary angioplasty would be good value.<sup>17</sup>

As is often the case in evaluating medical interventions, technologies advance more rapidly than the evidence base. Since the majority of the trials informing this analysis were undertaken, medical practice for the delivery of thrombolysis and primary angioplasty has changed. For example, a large proportion of patients undergoing primary angioplasty today will have stents and GPAs as adjuvant drugs. Where possible, assumptions have been used which are conservative with respect to primary angioplasty (ie, tend to underestimate its cost effectiveness). For example, the use of stents and GPAs has been included as part of the cost of the primary angioplasty procedure, although only a proportion of patients in the most recent trials included in our review used them, and thus their influence on the overall estimated effectiveness was low. A sensitivity analysis (not reported here) has been undertaken using the price of streptokinase and including trials using only fibrin-specific thrombolytic agents, with no major changes in the results.<sup>17</sup> Moreover, an increasing proportion of patients undergoing thrombolysis will later receive "rescue" percutaneous coronary intervention to achieve reperfusion or revascularisation before discharge. This would probably affect the cost and effectiveness of a strategy of initial thrombolysis. This is also likely to be true for a large proportion of patients receiving pre-hospital thrombolysis.<sup>34</sup>

The lack of individual patient data from the trials precludes an analysis of how the relative effectiveness and cost effectiveness of angioplasty varies between subgroups of patients defined by their clinical and sociodemographic factors, so cost effectiveness is presented for the "average" patient reflected in the evidence. Our analysis should not be used to determine whether an individual patient should or should not receive primary angioplasty, but may reflect how cost effective a primary angioplasty service might be, depending on mean call-to-balloon times for the population being served. Furthermore, it has to be recognised that patients in routine practice are likely to show some differences from those included in trials. There is some conflicting evidence on whether primary angioplasty will be more or less effective in routine practice.<sup>35–36</sup>

Some limitations to the analysis should be noted. First, the time between patients contacting emergency services and receiving thrombolysis is a predictor of efficacy.<sup>37–38</sup> However, this likely source of variability in cost effectiveness could not be explicitly included in the analysis owing to inconsistent reporting in the trials. Therefore, results presented here represent average time-to-needle (54.3 minutes), which is similar to the mean time-to-needle in the UK of 67 minutes (personal communication, Dr John Birkhead, UK Myocardial Infarction National Audit Project). Second, given that our

systematic review was an update of a previously published meta-analysis,<sup>10</sup> neither the effect of publication bias nor study quality were formally assessed. Third, ideally the analysis would have compared the full range of reperfusion strategies, including different thrombolytic agents, alternative modes of administration and the use of rescue or facilitated angioplasty.<sup>39–40</sup> These analyses represent significant extensions of the work presented here.

In conclusion, the analysis suggests that primary angioplasty is cost effective for the treatment of AMI, on the basis of threshold values used in the NHS, for a time delay of up to about 80 minutes.

## ACKNOWLEDGEMENTS

We gratefully acknowledge the contribution of our clinical Expert Advisory Group consisting of Drs David Gray, Rob Henderson and Jim McLenachan. The views expressed are those of the authors who are also responsible for any errors.



A supplementary technical report is available on the Heart website—<http://heart.bmj.com/supplemental>

## Authors' affiliations

**Yolanda Bravo Vergel, Stephen Palmer, Christian Asseburg, Mark Sculpher**, Centre for Health Economics, University of York, York, UK  
**Elisabeth Fenwick**, Public Health and Health Policy, University of Glasgow, Glasgow, UK  
**Mark de Belder**, The James Cook University Hospital, Middlesbrough, UK  
**Keith Abrams**, Centre for Biostatistics and Genetic Epidemiology, Department of Health Sciences, University of Leicester, UK

This study was funded by an unrestricted educational grant to the University of York from Cordis Ltd. The contract ensured the researchers' freedom to design, implement and publish their work. Mark Sculpher also received funding via a Career Award in Public Health funded by the NHS Research and Development Programme.

Competing interests: Mark Sculpher and Mark de Belder have received research funding and consultancy fees from various manufacturers of medical devices such as coronary stents. No other authors have competing interests to declare.

## REFERENCES

- 1 **Department of Health**. *National Service Framework for Coronary Heart Disease. Modern Standards and Service Models*. London: Department of Health, 2000.
- 2 **Office for National Statistics**. *National statistics online*. Available at <http://www.statistics.gov.uk> (accessed 20 June 2007).
- 3 **Department of Health**. *Coronary heart disease: leading the way - progress report 2005*. London: Department of Health, 2005.
- 4 **Petersen S, Peto V, Rayner M, et al**. *European cardiovascular disease statistics*. Oxford: University of Oxford, 2005.
- 5 **The GUSTO Angiographic investigators**. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. *N Engl J Med* 1993;**329**:1615–22.
- 6 **Bassand JP, Danchin N, Filippatos G, et al**. Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology. *Eur Heart J* 2005;**26**:2733–41.
- 7 **Smith D, Channer K**. Primary angioplasty should be first line treatment for acute myocardial infarction. For and against. *BMJ* 2004;**328**:1254–7.
- 8 **Smith E, Rothman M**. Isn't it time for primary angioplasty in the UK? *Br J Cardiol* 2003;**10**:66–70.
- 9 **British Cardiovascular Society**. <http://www.bcs.com> (accessed 20 June 2007).
- 10 **Keeley EC, Boura JA, Grines CL**. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. *Lancet* 2003;**361**:13–20.
- 11 **Asseburg C, Bravo Vergel Y, Palmer S, et al**. Assessing the effectiveness of primary angioplasty compared to thrombolysis and its relationship to time delay: a Bayesian evidence synthesis. *Heart* Published Online First:3 February 2007. doi: 10.1136/hrt.2006.093336..
- 12 **Cooper N, Sutton A, Abrams K, et al**. Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach. *Health Economics* 2004;**13**:203–26.
- 13 **Ades A, Sculpher M, Sutton A, et al**. Bayesian methods for evidence synthesis in cost-effectiveness analysis. *Pharmacoeconomics* 2006;**24**:1–19.
- 14 **Spiegelhalter DJ, Thomas A, Best NG, et al**. *WinBUGS user manual: version 1.4*. Cambridge: MRC Biostatistic Unit, 2001.
- 15 **National Institute for Clinical Excellence**. *Guide to the methods of technology appraisal*. London: NICE, 2004.
- 16 **Briggs A, Sculpher M**. Introducing Markov models for economic evaluation. *Pharmacoeconomics* 1998;**13**:397–409.
- 17 **Bravo Vergel Y, Palmer S, Asseburg C, et al**. *The cost-effectiveness of primary angioplasty compared to thrombolytic therapy for acute myocardial infarction in the UK NHS*. York: University of York, 2006.
- 18 **Department of Health**. *Hospital Episode Statistics, Vol 1. Finished consultant episodes by diagnosis and operative procedure. England: financial year 2003–04*. London: Department of Health, 2004.
- 19 **British Medical Association, Royal Pharmaceutical Society of Great Britain**. *British National Formulary: No. 49, March 2005*. London: BMA, Royal Pharmaceutical Society of Great Britain, 2005.
- 20 **Department of Health**. *Reference costs*. Leeds: Department of Health, 2004.
- 21 **Sculpher M, Smith DH, Clayton T, et al**. Coronary angioplasty versus medical therapy for angina. Health service costs based on the second Randomized Intervention Treatment for Angina (RITA-2) trial. *Eur Heart J* 2002;**23**:1291–300.
- 22 **Bagust A, Grayson A, Palmer N, et al**. Cost-effectiveness of drug-eluting coronary artery stenting in a UK setting: cost-utility study. *Heart* 2006;**92**:68–74.
- 23 **Rowley JM, Harrison EA, Skene AM, et al**. The management of myocardial infarction: implications for current practice derived from the Nottingham Heart Attack Register. *Br Heart J* 1992;**67**:255–62.
- 24 **Chambers M, Hutton J, Gladman J**. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole. *Pharmacoeconomics* 1999;**16**:577–93.
- 25 **Lacey P, Walters SJ**. Continuing inequality: gender and social class influences on self perceived health after a heart attack. *J Epidemiol Commun Health* 2003;**57**:622–7.
- 26 **Tengs T, Lin T**. A meta-analysis of quality of life estimates for stroke. *Pharmacoeconomics* 2003;**21**:191–200.
- 27 **Curtis L, Netten, A**. *Unit costs of health and social care (PSSRU)*. Kent: University of Kent, 2004.
- 28 **Johannesson M, Weinstein, S**. On the decision rules of cost-effectiveness analysis. *J Health Econ* 1993;**12**:459–67.
- 29 **Hartwell D, Colquitt J, Loveman E**. Clinical effectiveness and cost-effectiveness of immediate angioplasty for acute myocardial infarction: systematic review and economic evaluation. *Health Technol Assess* 2005;**9**:1–99.
- 30 **Mullner M, Paulis M, Nikfardjam M, et al**. Primary PTCA versus thrombolysis with tPA in acute myocardial infarction: a formal cost-effectiveness analysis. *Wien Klin Wochenschr* 1999;**111**:37–41.
- 31 **Lieu TA, Gurley RJ, Lundstrom RJ, et al**. Projected cost-effectiveness of primary angioplasty for acute myocardial infarction. *J Am Coll Cardiol* 1997;**30**:1741–50.
- 32 **Rafferty J**. NICE: faster access to modern treatments? Analysis of guidance on health technologies. *BMJ* 2001;**323**:1300–3.
- 33 **Spiegelhalter DJ, Abrams KR, Myles JP**. *Bayesian approaches to clinical trials and health-care evaluation*. Chichester: Wiley, 2004.
- 34 **Bonnefoy E, Lapostolle F, Leizorovicz A, for the CAPTIM study group, et al**. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. *Lancet* 2002;**360**:825–9.
- 35 **Boersma E, Group atPCAvTP-TC**. Does time matter? A pooled analysis of randomised clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. *Eur Heart J* 2006;**27**:779–88.
- 36 **Nallamothu BK, Bates ER, Herrin J, for the NRM1 investigators, et al**. Times to treatment in transfer patients undergoing primary PCI in the United States: National Registry of Myocardial Infarction (NRM1)-3/4 analysis. *Circulation* 2005;**111**:761–7.
- 37 **Boersma E, Maas AC, Deckers JW, et al**. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. *Lancet* 1996;**348**:771–5.
- 38 **Bjorklund E, Stenestrand U, Lindbach J, on behalf of the RIKS-HIA investigators, et al**. Pre-hospital thrombolysis delivered by paramedics is associated with reduced time delay and mortality in ambulance transported real-life patients with ST-elevation myocardial infarction. *Eur Heart J* 2006;**27**:1146–52.
- 39 **Fernandez-Aviles F, Alonso J, Castro-Beiras A, et al**. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. *Lancet* 2004;**364**:1045–53.
- 40 **Goff D, Sellers D, McGovern P, et al**. Knowledge of heart attack symptoms in a population survey in the United States. The REACT Trial. *Arch Intern Med* 1998;**158**:2329–38.